Alkermes plc (ALKS)


Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm
NEW YORK, January 25, 2019 / Globenewswire -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alkermes plc ("Alkermes" or the "Company")(NASDAQ:ALKS) of the February 25, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
If you invested in Alkermes stock or options between February 17, 2017 and November 1, 2018 and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.


The lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of all those who purchased Alkermes securities between February 17, 2017 and November 1, 2018 (the "Class Period"). The case, Karimian v. Alkermes Public Limited Company et al., No. 18-cv-07410 was filed on December 27, 2018, and has been assigned to Judge LaShann DeArcy Hall.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) the FDA had advised Alkermes to follow a certain protocol in connection with its NDA submission for ALKS 5461; (2) Alkermes had failed to follow that protocol; (3) consequently, an FDA advisory committee voted 21 to 2 against the approval of ALKS 5461; and (4) as a result, Alkermes’ public statements were materially false and/or misleading at all relevant times.
On April 2, 2018, Alkermes reported that it received a Refusal to File letter from the FDA regarding its NDA for ALKS 5461. The Company stated that "the FDA has taken the position that it is unable to complete a substantive review of the regulatory package, based on insufficient evidence of overall effectiveness for the proposed indication, and that additional well-controlled clinical trials are needed prior to the resubmission of the NDA for ALKS 5461."
On this news, Alkermes's share price fell from $57.96 per share on March 29, 2018 to a closing price of $45.23 on April 2, 2018: a $12.73 or a 21.96% drop.
On October 30, 2018, the FDA released a briefing document concerning Alkermes’ NDA for ALKS 5461. The briefing document stated the FDA did not agree with Alkermes’ methodologies and that Alkermes disregarded the FDA’s advice.
On this news, Alkermes's share price fell from $40.37 per share on October 29, 2018 to a closing price of $39.80 on October 30, 2018: a $0.57 or a 1.41% drop.
On November 1, 2018, Alkermes announced that the FDA advisory committee voted 21 to 2 against the approval of ALKS 5461. That same day, Xconomy reported that, "[a]t the hearing, FDA representatives said the agency specifically told Alkermes not to analyze its data through an average, which it still did."
On this news, Alkermes's share price fell from $40.83 per share on November 1, 2018 to a closing price of $37.74 on November 2, 2018: a $3.09 or a 7.57% drop.
 

Contact us

Alkermes plc (ALKS)

Loading captcha, please wait...

* The submission of this form does not create an attorney-client relationship.

Details

Filed on 01/07/2019

Ticker NASDAQ:ALKS

Office

685 Third Avenue 26th Floor

10017 New York, New York

Phone (212) 983-9330

Fax (212) 983-9331

Counsel

Richard W. Gonnello rgonnello@faruqilaw.com Phone (212) 983-9330 Fax (212) 983-9331

Finding us

Our Offices


Our offices are nationwide. If you have any questions about a case or our firm, please contact us.

New York

685 Third Avenue 26th Floor
New York, New York 10017
(212) 983-9330
(877) 247-4292
(212) 983-9331

California

10866 Wilshire Boulevard Suite 1470
Los Angeles, California 90024
(424) 256-2884
(424) 256-2885

Delaware

3828 Kennett Pike Suite 201
Wilmington, Delaware 19807
(302) 482-3182
(302) 482-3612

Georgia

3975 Roswell Rd Suite A
Atlanta, Georgia 30342
(404) 847-0617
(404) 506-9534

Pennsylvania

1617 JFK Boulevard, Suite 1550
Philadelphia, Pennsylvania 19103
(215) 277-5770
(215) 277-5771

Faruqi & Faruqi office in New York, New York

Faruqi & Faruqi office in Los Angeles, California

Faruqi & Faruqi office in Wilmington, Delaware

Faruqi & Faruqi office in Atlanta, Georgia

Faruqi & Faruqi office in Philadelphia, Pennsylvania